Stockholm - Delayed Quote SEK

Implantica AG (IMP-A-SDB.ST)

37.00
-0.20
(-0.54%)
At close: May 23 at 5:29:56 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Dr. Peter Forsell Founder & CEO 208.35k -- 1954
Mr. Andreas Öhrnberg Chief Financial Officer -- -- 1978
Mr. Stephan Siegenthaler Chief Strategy Officer & Board Member -- -- 1957
Ms. Nicole Pehrsson Chief Corporate Affairs Officer -- -- 1966
Ms. Juanita Eberhart Vice President of Marketing & Advocacy -- -- --
Mr. Amit Kukreja Chief Market Access & Strategy Officer -- -- 1983
Ms. Melanie Houselog Senior Director & Head of Global QA RA -- -- --
Mr. Jörg von Manger-Koenig Company Secretary & Member of Advisory Board -- -- 1960

Implantica AG

Aeulestrasse 45
Vaduz, 9490
Liechtenstein
https://www.implantica.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
50

Description

Implantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.

Corporate Governance

Implantica AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 14, 2025 at 6:00 AM UTC

Implantica AG Earnings Date

Recent Events

Related Tickers